Lenumlostat

PAT-1251 is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with IC50s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC50s, 0.10, 0.12, and 0.16 μM, respectively) ; PAT-1251 is used in the research of fibrotic diseases[1].

Product Specifications

CAS Number

[2007885-39-2]

Product Name Alternative

PAT-1251; GB2064

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lenumlostat.html

Purity

99.52

Solubility

DMSO : ≥ 130 mg/mL|H2O : ≥ 100 mg/mL

Smiles

O=C(C1=CC=CC(OC2=NC(C(F)(F)F)=CC(CN)=C2)=C1)N3C[C@@H](F)[C@H](O)C3

Molecular Formula

C18H17F4N3O3

Molecular Weight

399.34

Precautions

H302, H315, H319, H335

References & Citations

[1]Rowbottom MW, et al. Identification of 4- (Aminomethyl) -6- (trifluoromethyl) -2- (phenoxy) pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2) . J Med Chem. 2017 May 25;60 (10) :4403-4423.